[go: up one dir, main page]

PE20181952A1 - Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos - Google Patents

Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos

Info

Publication number
PE20181952A1
PE20181952A1 PE2018002029A PE2018002029A PE20181952A1 PE 20181952 A1 PE20181952 A1 PE 20181952A1 PE 2018002029 A PE2018002029 A PE 2018002029A PE 2018002029 A PE2018002029 A PE 2018002029A PE 20181952 A1 PE20181952 A1 PE 20181952A1
Authority
PE
Peru
Prior art keywords
cdr
seq
group
kabat numbering
antibody
Prior art date
Application number
PE2018002029A
Other languages
English (en)
Inventor
Laird Bloom
Karl Henry Nocka
James Reasoner Apgar
Mark A Farmer
Matthew Allister Lambert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20181952A1 publication Critical patent/PE20181952A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)

Abstract

Referido a un anticuerpo o fragmento de union al antigeno del mismo, que se une especificamente a interleucina 33 (IL-33) humana, caracterizado porque comprende cualquiera de: (i) una CDR-L1 seleccionada del grupo que consiste de SEQ ID NO: 20, 37, 190, 193, 257, 258, 259 y 260 de acuerdo con la numeracion Kabat; (ii) una CDR-L2 seleccionada del grupo que consiste de SEQ ID NO: 21, 196, 199, 261, 262, 263, y 264 de acuerdo con la numeracion Kabat; (iii) una CDR-L3 seleccionada del grupo que consiste de SEQ ID NO: 22, 38, 208, 265, 26, 267 y 268 de acuerdo con la numeracion Kabat; (iv) una CDR-H1 seleccionada del grupo que consiste de SEQ ID NO: 16, 33, 269, 270 y 271 de acuerdo con la numeracion Kabat; (v) una CDR-H2 seleccionada del grupo que consiste de SEQ ID NO: 17, 34, 168, 171 ,174, 180, 202, 205, 211, 214, 217, 220, 223, 226, 229, 232, 235, 272, 273, 274, y 275 de acuerdo con la numeracion Kabat, y (vi) una CDR-H3 seleccionada del grupo que consiste de SEQ ID NO: 18, 35, 114, 119, 122, 127, 130, 133, 136, 139, 142, 145, 148, 153, 156, 159, 177, 187, 276, 277, 278, y 279 de acuerdo con la numeracion Kabat. En donde, este anticuerpo o fragmento de union al antigeno del mismo, comprende una o ambas secuencias de marco VL y VH es al menos 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% o 99% identica a la secuencia de la linea germinal de humano a partir de la cual se deriva. Tambien se refiere a una molecula aislada de acidos nucleicos, un vector, una celula huesped y un metodo para elaborar un anticuerpo. Una composicion farmaceutica que comprende un anticuerpo y metodos para tratar enfermedades inflamatorias, alergias, entre otras.
PE2018002029A 2016-04-27 2017-04-20 Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos PE20181952A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328294P 2016-04-27 2016-04-27
US201762483781P 2017-04-10 2017-04-10

Publications (1)

Publication Number Publication Date
PE20181952A1 true PE20181952A1 (es) 2018-12-17

Family

ID=58632552

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002029A PE20181952A1 (es) 2016-04-27 2017-04-20 Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos

Country Status (17)

Country Link
US (2) US10544212B2 (es)
EP (1) EP3448888A1 (es)
JP (1) JP2019516362A (es)
KR (1) KR20180128028A (es)
CN (1) CN109415436A (es)
AU (1) AU2017257330A1 (es)
BR (1) BR112018071276A2 (es)
CA (1) CA2965089A1 (es)
CO (1) CO2018011364A2 (es)
IL (1) IL262497A (es)
MX (1) MX2018013038A (es)
PE (1) PE20181952A1 (es)
PH (1) PH12018502225A1 (es)
RU (1) RU2740309C2 (es)
SG (1) SG11201808693WA (es)
TW (2) TWI679211B (es)
WO (1) WO2017187307A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
EP3783023A1 (en) 2014-11-10 2021-02-24 H. Hoffnabb-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
EP3638697A4 (en) 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
IL275073B2 (en) 2017-12-12 2025-11-01 Pionyr Immunotherapeutics Inc Anti-trem2 antibodies and related methods
CN111936514A (zh) * 2018-03-30 2020-11-13 美勒斯公司 多价抗体
IL307286B1 (en) 2018-04-11 2025-11-01 Regeneron Pharma Methods and compositions for quantifying il-33
WO2020123664A1 (en) * 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
CN112480252B (zh) * 2019-09-12 2023-02-07 上海麦济生物技术有限公司 抗白细胞介素-33抗体及其制备方法和应用
EP4034165A4 (en) 2019-09-25 2023-10-25 The General Hospital Corporation THERAPEUTIC NEUTRALIZATION ANTIBODIES FOR THE TREATMENT OF PEANUT ALLERGY
US20220380450A1 (en) 2019-11-04 2022-12-01 Medimmune Limited Methods of using il-33 antagonists
CA3158366A1 (en) * 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
CN113214395A (zh) * 2020-01-21 2021-08-06 迈威(上海)生物科技股份有限公司 抗st2抗体及其应用
EP4118236A1 (en) 2020-03-13 2023-01-18 MedImmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
IL296853A (en) * 2020-04-06 2022-11-01 Medimmune Ltd Treatment of acute respiratory distress syndrome with il-33 axis binding antagonists
WO2021228760A1 (en) 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
EP4151654A4 (en) * 2020-05-12 2024-11-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
CN111620948B (zh) * 2020-06-10 2022-04-08 南京赛新生物科技有限公司 针对il-33的抗体
KR102789102B1 (ko) * 2020-08-18 2025-03-28 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
CN117858898A (zh) * 2021-08-27 2024-04-09 免疫医疗有限公司 用抗白介素-33抗体治疗慢性阻塞性肺病
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023108101A1 (en) * 2021-12-09 2023-06-15 Emory University Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions
CN114397289A (zh) * 2022-01-14 2022-04-26 长春工业大学 一种土壤中重金属元素定量分析方法及相关设备
JP2025508835A (ja) * 2022-02-24 2025-04-10 シノマブ バイオサイエンス リミテッド アラーミンに対する二重特異性結合タンパク質およびその使用
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
CN119923406A (zh) 2022-08-19 2025-05-02 免疫医疗有限公司 选择患者以用il-33轴拮抗剂进行治疗的方法
CN115947844B (zh) * 2022-12-09 2024-06-14 江苏荃信生物医药股份有限公司 一种新的抗人il-33单克隆抗体、包含其的试剂盒及其检测方法
AR134489A1 (es) * 2023-11-27 2026-01-21 Glaxosmithkline Ip Dev Ltd Proteinas de unión a antígeno
WO2025120567A1 (en) 2023-12-07 2025-06-12 Medimmune Limited Method of treatment of asthma
TW202540173A (zh) 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法
WO2025242618A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Bronchiectasis treatment

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
PT2263692T (pt) 2002-12-24 2018-11-28 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2686683A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
CN112481367A (zh) 2008-03-31 2021-03-12 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
MX341958B (es) 2011-02-23 2016-09-08 Hoffmann La Roche Anticuerpos contra el il33r humano y usos de los mismos.
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
EP2817417B1 (en) 2012-02-24 2017-10-25 Children's Hospital Medical Center Esophageal microrna expression profiles in eosinophilic esophagitis
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
AU2013320355B2 (en) 2012-09-19 2018-06-14 Innate Pharma KIR3DL2 binding agents
WO2014062621A1 (en) 2012-10-15 2014-04-24 Stc.Unm Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
BR112016013347B1 (pt) * 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
RU2693084C2 (ru) * 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
EP3783023A1 (en) 2014-11-10 2021-02-24 H. Hoffnabb-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
CN108064236B (zh) 2015-03-31 2021-12-10 免疫医疗有限公司 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
MX2018004170A (es) 2015-10-06 2018-06-06 Regeneron Pharma Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
WO2017124110A1 (en) 2016-01-14 2017-07-20 Anaptysbio, Inc. Inhibition of allergic reaction using an il-33 inhibitor

Also Published As

Publication number Publication date
CN109415436A (zh) 2019-03-01
TW201943729A (zh) 2019-11-16
US20200308272A1 (en) 2020-10-01
TW201808995A (zh) 2018-03-16
IL262497A (en) 2018-12-31
RU2018137811A3 (es) 2020-05-27
RU2018137811A (ru) 2020-05-27
AU2017257330A1 (en) 2018-10-18
PH12018502225A1 (en) 2019-08-19
US10544212B2 (en) 2020-01-28
CA2965089A1 (en) 2017-10-27
JP2019516362A (ja) 2019-06-20
CO2018011364A2 (es) 2018-11-13
MX2018013038A (es) 2019-03-28
BR112018071276A2 (pt) 2019-02-12
WO2017187307A1 (en) 2017-11-02
RU2740309C2 (ru) 2021-01-13
KR20180128028A (ko) 2018-11-30
TWI679211B (zh) 2019-12-11
EP3448888A1 (en) 2019-03-06
SG11201808693WA (en) 2018-11-29
US20180037644A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
PE20210554A1 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
PE20121646A1 (es) Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
PE20121647A1 (es) Proteinas terapeuticas de union a dll4
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
PE20040947A1 (es) MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PE20211605A1 (es) ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
PE20191076A1 (es) Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
JP2020524510A5 (es)
PE20191075A1 (es) Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo
CO6311009A2 (es) Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu
AR124895A1 (es) Anticuerpos anti-cd30l y usos de estos
PE20181051A1 (es) Anticuerpo anti-epha4